EUVIMEDEUVIMED entdecken
Crossref

Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab

Jun Won Park iD, Jeffrey R Curtis iD, Se Rim Choi, Min Jung Kim, You-Jung Ha, Eun Ha Kang iD, Yun Jong Lee iD, Eun Bong Lee iD

Arthritis & Rheumatology · 2023-11 · 75 (11) · 2036-2044

DOI: 10.1002/art.42541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 22.08.2023. Verfasst von Jun Won Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Rheumatic Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify a specific population of patients with rheumatic diseases receiving rituximab treatment for whom the benefit from primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) outweighs the risk of adverse events (AEs).

Methods

This study included 818 patients treated with rituximab for rheumatic diseases, among whom 419 received prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) with rituximab, while the remainder did not. Differences in 1‐year PJP incidence between the groups were estimated using Cox proportional hazards regression. Risk–benefit assessment was performed in subgroups stratified according to risk factors based on the number needed to treat (NNT) to prevent 1 case of PJP and the number needed to harm (NNH) due to severe AEs. Inverse probability of treatment weighting was applied to minimize the confounding by indication.

Results

During the 663.1 person‐years, there were 11 PJP cases, with a mortality rate of 63.6%. Concomitant use of high‐dose glucocorticoids (≥30 mg/day of prednisone or equivalent during 4 weeks after rituximab administration) was the most important risk factor. The PJP incidence (per 100 person‐years) was 7.93 (95% confidence interval [95% CI] 2.91–17.25) in the subgroup receiving high‐dose glucocorticoids compared with 0.40 (95% CI 0.01–2.25) in the subgroup without high‐dose glucocorticoid use. Although prophylactic TMP/SMX significantly reduced the overall PJP incidence (HR 0.11 [95% CI 0.03–0.43]), the NNT to prevent 1 case of PJP (146) was higher than the NNH (86). In contrast, the NNT fell to 20 (95% CI 10.7–65.7) in patients receiving concomitant high‐dose glucocorticoids.

Conclusion

The benefit associated with primary PJP prophylaxis outweighs the risk of severe AEs in patients with rheumatic diseases receiving rituximab and concomitant high‐dose glucocorticoid treatment. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, PneumocystisRheumatic DiseasesHumansTrimethoprim, Sulfamethoxazole Drug CombinationRituximabGlucocorticoidsRetrospective Studies

Substanzen

Trimethoprim, Sulfamethoxazole Drug CombinationRituximabGlucocorticoids

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham.
  • Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University, Boramae Medical Center, Seoul, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, and Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital,…
  • Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, and Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Scienc…

ORCID-Profile: Jun Won Park, Jeffrey R Curtis, Eun Ha Kang, Yun Jong Lee, Eun Bong Lee

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Park, J. W., Curtis, J. R., Choi, S. R., Kim, M. J., Ha, Y. J., Kang, E. H., Lee, Y. J., & Lee, E. B. (2023). Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis & Rheumatology, 75(11), 2036-2044. https://doi.org/10.1002/art.42541

Vancouver

Park JW, Curtis JR, Choi SR, Kim MJ, Ha YJ, Kang EH, et al. Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis & Rheumatology. 2023;75(11):2036-2044. doi:10.1002/art.42541

BibTeX
@article{Park2023,
  author = {Park, Jun Won and Curtis, Jeffrey R and Choi, Se Rim and Kim, Min Jung and Ha, You-Jung and Kang, Eun Ha and Lee, Yun Jong and Lee, Eun Bong},
  title = {Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  volume = {75},
  number = {11},
  pages = {2036--2044},
  doi = {10.1002/art.42541}
}
Kostenlos starten →